Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07224737 · ClinicalTrials.gov registry record
Liquid Biopsy Using Exosomal miRNA Enables Risk Stratification of Potential Metastasis in Patients With Intrahepatic Cholangiocarcinoma.
A clinical trial, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- 230
- Enrollment target
NCT07224737 is a clinical trial that has completed, run by City of Hope Medical Center. The registered enrollment target is 230 participants.
The verdict
NCT07224737 has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- 230 participants
- Enrollment target
Study Summary
Occult metastasis at the time of surgery is a major driver of poor outcomes in intrahepatic cholangiocarcinoma (ICC), yet reliable preoperative biomarkers to identify such patients are lacking. The EXOMIC study aims to develop and validate a circulating exosomal microRNA (exo-miRNA)-based liquid biopsy assay to detect occult metastasis preoperatively in patients with resectable ICC.
Interventions
- DIAGNOSTIC_TEST EXOMIC small RNA sequencing
- DIAGNOSTIC_TEST EXOMIC assay (qRT-PCR validation)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2024-06-21 |
| Est. Completion | 2026-02-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07224737
The ClinicalTrials.gov registry entry for NCT07224737 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which EXOMIC small RNA sequencing is the first listed.
NCT07224737 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07224737 about?
NCT07224737 is a clinical study titled "Liquid Biopsy Using Exosomal miRNA Enables Risk Stratification of Potential Metastasis in Patients With Intrahepatic Cholangiocarcinoma.". Occult metastasis at the time of surgery is a major driver of poor outcomes in intrahepatic cholangiocarcinoma (ICC), yet reliable preoperative biomarkers to identify such patients are lacking. The EXOMIC study aims to develop and validate a circulating exosomal microRNA (exo-miRNA)-based liquid bio...
What is the current status of trial NCT07224737?
This trial is currently completed. The enrollment target is 230 participants. The study started on 2024-06-21. Estimated completion is 2026-02-18.
What interventions are being tested in trial NCT07224737?
The interventions under investigation include: EXOMIC small RNA sequencing (DIAGNOSTIC_TEST), EXOMIC assay (qRT-PCR validation) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07224737?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.